ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

18 links0 made here, not in the record25 judgments2 judges (the rules as one: Rule based)1 record change seen
Claude Opus 5.5Rule basedRecord updated on ClinicalTrials.gov
Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT03432741Direct Tumor Microinjectionand FDG-PET in Testing DrugSensitivity in PatientsWith Relapsed or RefractoryNon-Hodgkin Lymphoma,Hodgkin Lymphoma, or StageIV Breast CancerMayo ClinicPhase 1 · terminatedRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Nov 8 · ClinicalTrials.gov record · MeSH filing re-derivedMeSH filing re-derivedCONDITIONSBreast NeoplasmsThe registry's MeSH filing›As of now · Rule based · Main conditionMain conditionHodgkin DiseaseThe registry's MeSH filing›No judgment recorded. Shown as the registry files it.Mycosis FungoidesThe registry's MeSH filing›No judgment recorded. Shown as the registry files it.Lymphoma, Non-HodgkinThe registry's MeSH filing›No judgment recorded. Shown as the registry files it.Lymphoma, T-Cell, CutaneousThe registry's MeSH filing›No judgment recorded. Shown as the registry files it.Lymphoma, B-Cell, Marginal …The registry's MeSH filing›No judgment recorded. Shown as the registry files it.DRUGSBelinostatIntervention entry›Nov 2 · Claude Opus 5.5 · ProcedureNov 18 · Rule based · BackgroundProcedureCarfilzomibIntervention entry›Nov 2 · Claude Opus 5.5 · ProcedureNov 18 · Rule based · BackgroundProcedureCopanlisib hydrochlorideIntervention entry›Nov 2 · Claude Opus 5.5 · ProcedureNov 18 · Rule based · BackgroundProcedureDaratumumabIntervention entry›Nov 2 · Claude Opus 5.5 · ProcedureNov 18 · Rule based · BackgroundProcedureFluorodeoxyglucose F18Entry “Fludeoxyglucose F-18”, read by…›Nov 2 · Claude Opus 5.5 · ProcedureNov 18 · Rule based · TestedProcedureGemcitabineEntry “Gemcitabine Hydrochloride”, re…›Nov 2 · Claude Opus 5.5 · ProcedureNov 18 · Rule based · BackgroundProcedureNivolumabIntervention entry›Nov 2 · Claude Opus 5.5 · ProcedureNov 18 · Rule based · BackgroundProcedureObinutuzumabIntervention entry›Nov 2 · Claude Opus 5.5 · ProcedureNov 18 · Rule based · BackgroundProcedurePembrolizumabIntervention entry›Nov 2 · Claude Opus 5.5 · ProcedureNov 18 · Rule based · BackgroundProcedureRituximabIntervention entry›Nov 2 · Claude Opus 5.5 · ProcedureNov 18 · Rule based · BackgroundProcedureRomidepsinIntervention entry›Nov 2 · Claude Opus 5.5 · ProcedureNov 18 · Rule based · BackgroundProcedureTrastuzumabIntervention entry›Nov 2 · Claude Opus 5.5 · Background · careNov 18 · Rule based · BackgroundBackground · care

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

Belinostat

From the registry record2 judgments on this link
Role in the study, from the registry to what was judged
RegistryEntry “Belinostat”the record gives no role
→judged→changed
How the 2 judgments split50%of judgments with a known value say Procedure
Procedure · 1
Background · 1

All judgments on this study

WhenLinkJudgeDecisionState
Nov 2BelinostatClaude Opus 5.5ProcedureCurrent
Nov 2CarfilzomibClaude Opus 5.5ProcedureCurrent
Nov 2Copanlisib hydrochlorideClaude Opus 5.5ProcedureCurrent
Nov 2DaratumumabClaude Opus 5.5ProcedureCurrent
Nov 2Fluorodeoxyglucose F18Claude Opus 5.5ProcedureCurrent
Nov 2GemcitabineClaude Opus 5.5ProcedureCurrent
Nov 2NivolumabClaude Opus 5.5ProcedureCurrent
Nov 2ObinutuzumabClaude Opus 5.5ProcedureCurrent
Nov 2PembrolizumabClaude Opus 5.5ProcedureCurrent
Nov 2RituximabClaude Opus 5.5ProcedureCurrent
Nov 2RomidepsinClaude Opus 5.5ProcedureCurrent
Nov 2TrastuzumabClaude Opus 5.5Background · careCurrent
Nov 8The record itselfClinicalTrials.gov recordMeSH filing re-derivedRecord change
Nov 18BelinostatRule based · role ruleBackgroundOverridden
Nov 18CarfilzomibRule based · role ruleBackgroundOverridden
Nov 18Copanlisib hydrochlorideRule based · role ruleBackgroundOverridden
Nov 18DaratumumabRule based · role ruleBackgroundOverridden
Nov 18Fluorodeoxyglucose F18Rule based · role ruleTestedOverridden
Nov 18GemcitabineRule based · role ruleBackgroundOverridden
Nov 18NivolumabRule based · role ruleBackgroundOverridden
Nov 18ObinutuzumabRule based · role ruleBackgroundOverridden
Nov 18PembrolizumabRule based · role ruleBackgroundOverridden
Nov 18RituximabRule based · role ruleBackgroundOverridden
Nov 18RomidepsinRule based · role ruleBackgroundOverridden
Nov 18TrastuzumabRule based · role ruleBackgroundAgrees
As of nowBreast NeoplasmsRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.